The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to provide a significant substantial decrease in body size and improve metabolic markers, par